Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction

ClinicalTrials.gov ID: NCT02559219

Public ClinicalTrials.gov record NCT02559219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction is a pilot project designed to test the feasibility and acceptability of use of an online care plan generator for adult survivors of pediatric cancers. Because of improvements in cancer screening, diagnosis and treatment, there are an estimated 13 million cancer survivors living in the U.S. today, with projected growth to 18 million by 2020 (De Moor). These survivors include survivors of leukemia and lymphoma, as well as solid tumors including breast, colon, testicular and prostate cancers. It also include a subset of patients who are survivors of pediatric cancers, as over 80% of children diagnosed with cancer today are cured. In fact, it is estimated that 1 in every 600 young adults between the ages of 20-35 is a cancer survivor (Dreyer, Hewitt, Greenlee). Cancer patients as a whole, despite improved cure rates, have been shown to receive inadequate medical care as survivors. Comprehensive survivorship care should include routine age appropriate medical care as well as information about prior diagnosis and treatment, and screening for recurrence of their primary malignancy as well as secondary malignancies, and screening for late effects of cancer treatment (Earle, Craig). Adult survivors of pediatric cancer, exposed to life-saving but toxic treatments during times of growth and development, are particularly prone to late effects but also have been shown to have inadequate monitoring and follow up. This is a concern as late effects of treatment are sometimes silent for years or decades after completion of cancer therapy and that adult survivors of childhood cancer, years from their diagnosis and treatment, have been shown to have alarming rates of life threatening chronic health conditions compared to their peers (Oeffinger). Thus, these late effects may emerge during adulthood when patients have moved on from the care of their primary oncologist. Complicating matters, primary care providers, who often assume the care of these patients, may not have the knowledge or tools necessary to appropriately care for survivors of childhood cancer (Suh). National organizations have come together to identify ways to improve quality of and access to long term follow up care for adult survivors of childhood cancer. The Children's Oncology Group published Long Term Follow up guidelines which recommend lifelong risk based follow up care and screening (COG guidelines). In addition, in 2005, the Institute of Medicine published a report, From Cancer Patient to Cancer Survivor: Lost in Transition gave recommendations to improve health outcomes of cancer survivors which includes the receipt of a comprehensive care summary and follow up plan to aid in appropriate risk based follow up care (Hewitt). Despite these recommendations childhood cancer survivors knowledge about past diagnosis and treatment and engagement in follow up care is suboptimal (Kaden-Lottick, Nathan). It has been demonstrated that pediatric cancer survivors are not receiving care summaries, and thus may try to find appropriate follow up information via the other sources such as the internet (Casillas). Oncolife, a free online tool to create survivorship care plans, was created in May 2007 (Hill 2009), and has been housed at maintained at the University of Pennsylvania since then. This tool has shown to be feasible way to provide information and care plans to survivors of adult cancers. In addition, survivors who have used the resource, state that it will, or has already, positively influenced communication about cancer related follow up with their healthcare team (Hill 2013). The study aim is to adapt Oncolife to provide individualized information for adult survivors of childhood cancer with the unique recommendations for long term follow up for pediatric cancer survivors. Oncolife has already been collecting data on plans created by adult survivors of adult cancers and has been reviewed by the IRB previously (IRB#806368 and #811528 note: previously called Oncolink). Adaption of Oncolife to meet the needs of adult survivors of childhood cancer will improve access to high quality electronic health information as patients may find long term follow up guidelines cumbersome or largely irrelevant to their needs depending on their specific exposures. Individualizing the available information to a particular survivor will allow for better understanding of and improved adherence to recommended cancer related follow up care. We propose to develop survivorship care plans in a way that will most benefit users, thus after creation of the Smart Adult Living After Childhood Cancer care plan we will ask for patient input via survey immediately after receipt of their care plan and in a one month follow up survey.

Study identification

NCT ID
NCT02559219
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Enrollment
30 participants

Conditions and interventions

Interventions

Other

Eligibility (public fields only)

Age range
15 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2014 (Type not available)
Primary completion
Sep 2016 (Actual)
Completion
Sep 16, 2016 (Actual)
Last update posted
Apr 24, 2020

2014 – 2016

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania 19104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02559219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2020 · Synced Oct 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02559219 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →